| camlipixant (GSK5464714) / GSK |
2022-000188-38: A Phase 3, 24-Week, Randomized, Efficacy and Safety Study with Open-label Extension of BLU-5937 in Adult Participants with Refractory or Unexplained Chronic Cough |
|
|
| Not yet recruiting | 3 | 675 | RoW, Europe | BLU-5937, BLU-5937, Film-coated tablet | Bellus Health, Inc., Bellus Health, Inc. | Refractory or Unexplained Chronic Cough, Chronic Cough, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
| Recruiting | 3 | 825 | Europe, Canada, US, RoW | BLU-5937, Placebo | Bellus Health Inc. - a GSK company, Bellus Health, Inc. | Refractory Chronic Cough | 09/25 | 03/26 | | |
|
CALM-2, NCT05600777: A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough |
|
|
| Recruiting | 3 | 825 | Europe, US, RoW | BLU-5937, Placebo | Bellus Health Inc. - a GSK company | Refractory Chronic Cough | 09/25 | 06/26 | | |
2019-000375-16: A Study Of The Efficacy, Safety, And Tolerability of BLU-5937 for the Treatment of Chronic Cough with no Apparent Cause |
|
|
| Not yet recruiting | 2 | 51 | Europe | BLU-5937, Tablet | Bellus Health Inc., Bellus Health Inc. | Unexplained or Refractory Chronic Cough, Chronic cough with no apparent cause, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
NCT06179537: Evaluation of the Pharmacokinetics and Safety of BLU-5937 in Healthy Adult Japanese and Caucasian Subjects |
|
|
| Completed | 1 | 34 | Europe | BLU-5937 | Bellus Health Inc. - a GSK company | Healthy | 10/21 | 11/21 | | |
NCT05570539: Assessment of the Pharmacokinetics of BLU-5937 Extended Release Prototypes and a BLU-5937 Immediate Release Reference Formulation |
|
|
| Completed | 1 | 14 | Europe | BLU-5937 IR, BLU-5937 ER | Bellus Health Inc. - a GSK company | Cough, Healthy | 05/24 | 07/24 | | |
|
NCT05899829: Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant |
|
|
| Completed | 1 | 32 | Canada | Camlipixant + Rifampin, Camlipixant + Rabeprazole | Bellus Health Inc. - a GSK company | Healthy | 08/23 | 08/23 | | |
NCT05959447: Evaluation of the Potential Drug-drug Interactions Between Gemfibrozil or Dabigatran Etexilate and Camlipixant |
|
|
| Completed | 1 | 32 | Canada | Camlipixant + Gemfibrozil, Dabigatran etexilate + camlipixant | Bellus Health Inc. - a GSK company | Healthy | 10/23 | 10/23 | | |
NCT06222892: A Study of Camlipixant in Male and Female Healthy Participants and Participants With Hepatic Impairment Aged 18-75 Years of Age |
|
|
| Recruiting | 1 | 32 | US | Camlipixant | Bellus Health Inc. - a GSK company | Cough | 10/24 | 11/24 | | |
NCT06497517: A Study to Investigate the Effect of Food on Camlipixant Concentrations in Healthy Participants |
|
|
| Recruiting | 1 | 14 | US | GSK5464714- Camlipixant, Camlipixant | Bellus Health Inc. - a GSK company | Cough | 08/24 | 08/24 | | |
